Valéria Maria de Oliveira Cardoso
Research Subjects
Valéria Maria de Oliveira Cardoso has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Maria Palmira Daflon Gremião
4 shared publications- Natália Noronha Ferreira
Sao Carlos Institute of Physics, University of Sao Paulo, IFSC − USP, 13566-590 Sao Carlos, SP, Brazil
4 shared publications - Fernanda Isadora Boni
Universidade Federal do Rio Grande do Sul (UFRGS), Brasil
3 shared publications - Maria Palmira Daflon Gremião
School of Pharmaceutical Sciences, São Paulo State University, Rodovia Araraquara—Jaú Km 1, Araraquara 14800-903, SP, Brazil
3 shared publications - Valtencir Zucolotto
University of São Paulo
3 shared publications Beatriz Stringhetti Ferreira Cury
2 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Photoresponsive Nanocarriers for Potentiating Tuberculosis Therapy
Drug-resistant and multidrug-resistant tuberculosis (TB) remain major challenges to effective treatment. Given that TB arises from complex bacterial survival mechanisms, addressing this multifactorial disease requires innovative and combinatorial therapeutic approaches. Although various strategies have been employed to overcome these issues, concerns regarding therapeutic efficacy persist due to the prolonged treatment duration and high toxicity. Here, we developed photoresponsive nanocarriers coencapsulating isoniazid (INH) and rifampicin (RIF), with or without gold nanorods (AuNRs), as a multifunctional platform for laser-assisted TB therapy. AuNRs were synthesized and functionalized with PLGA-SH to enable photothermal activation and integration into polymeric carriers. The resulting systems exhibited an average size of approximately 180 nm, zeta potentials around −28 mV, particle concentrations on the order of 1011 particles mL–1, as measured by nanoparticle tracking analysis, and average encapsulation efficiencies of 90% for both drugs. In vitro, photoactivated nanocarriers significantly reduced Mycobacterium tuberculosis burden in murine alveolar epithelial (MLE-15) cells and macrophages (BMDMs), as well as in human macrophages (THP-1), without inducing cytotoxicity. TB preclinical models demonstrated that laser-triggered nanocarriers significantly reduced pulmonary bacterial load in infected mice compared with untreated groups, even at low doses. These findings demonstrate that the formulation’s therapeutic efficacy depends on photothermal activation and support its potential as an adjuvant strategy for precision, light-assisted TB treatment, thereby reducing systemic exposure and minimizing toxicity.
- 13 May 2026
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Open AccessPhotoresponsive Nanocarriers for Potentiating Tuberculosis Therapy
Drug-resistant and multidrug-resistant tuberculosis (TB) remain major challenges to effective treatment. Given that TB arises from complex bacterial survival mechanisms, addressing this multifactorial disease requires innovative and combinatorial therapeutic approaches. Although various strategies have been employed to overcome these issues, concerns regarding therapeutic efficacy persist due to the prolonged treatment duration and high toxicity. Here, we developed photoresponsive nanocarriers coencapsulating isoniazid (INH) and rifampicin (RIF), with or without gold nanorods (AuNRs), as a multifunctional platform for laser-assisted TB therapy. AuNRs were synthesized and functionalized with PLGA-SH to enable photothermal activation and integration into polymeric carriers. The resulting systems exhibited an average size of approximately 180 nm, zeta potentials around −28 mV, particle concentrations on the order of 1011 particles mL–1, as measured by nanoparticle tracking analysis, and average encapsulation efficiencies of 90% for both drugs. In vitro, photoactivated nanocarriers significantly reduced Mycobacterium tuberculosis burden in murine alveolar epithelial (MLE-15) cells and macrophages (BMDMs), as well as in human macrophages (THP-1), without inducing cytotoxicity. TB preclinical models demonstrated that laser-triggered nanocarriers significantly reduced pulmonary bacterial load in infected mice compared with untreated groups, even at low doses. These findings demonstrate that the formulation’s therapeutic efficacy depends on photothermal activation and support its potential as an adjuvant strategy for precision, light-assisted TB treatment, thereby reducing systemic exposure and minimizing toxicity.
- Open Access
- 9 April 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (17) , 16204-16223
Cancer Nanovaccines: Mechanisms, Design Principles, and Clinical Translation
Cancer immunotherapy has transformed the landscape of oncological treatment by employing various strategies to teach the immune system to eliminate tumors. Among these, cancer nanovaccines are an emerging strategy that utilizes nanotechnology to enhance immune activation in response to tumor antigens. This review addresses the principles behind the different technologies in this field aimed at generating a robust and effective immune response. The diversity of strategies adopted for the design of nanovaccines is discussed, including the types of active agents, nanocarriers, their functionalizations, and the incorporation of adjuvants. Furthermore, strategies to optimize nanoparticle formulations to enhance the antigen presentation, target immune cells, and organs and promote strong and durable antitumor responses are explored. Finally, we analyze the current state of clinical application, highlighting ongoing clinical trials and the future potential of cancer nanovaccines. The insights presented in this review aim to guide future research and development efforts in the field, contributing to the advancement of more effective and targeted nanovaccines in the fight against cancer.
- 9 April 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (17) , 16204-16223
Open AccessCancer Nanovaccines: Mechanisms, Design Principles, and Clinical Translation
Cancer immunotherapy has transformed the landscape of oncological treatment by employing various strategies to teach the immune system to eliminate tumors. Among these, cancer nanovaccines are an emerging strategy that utilizes nanotechnology to enhance immune activation in response to tumor antigens. This review addresses the principles behind the different technologies in this field aimed at generating a robust and effective immune response. The diversity of strategies adopted for the design of nanovaccines is discussed, including the types of active agents, nanocarriers, their functionalizations, and the incorporation of adjuvants. Furthermore, strategies to optimize nanoparticle formulations to enhance the antigen presentation, target immune cells, and organs and promote strong and durable antitumor responses are explored. Finally, we analyze the current state of clinical application, highlighting ongoing clinical trials and the future potential of cancer nanovaccines. The insights presented in this review aim to guide future research and development efforts in the field, contributing to the advancement of more effective and targeted nanovaccines in the fight against cancer.
- Open Access
- 31 December 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (9) , 13197-13220
Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy
Lung cancer remains a challenge within the realm of oncology. Characterized by late-stage diagnosis and resistance to conventional treatments, the currently available therapeutic strategies encompass surgery, radiotherapy, chemotherapy, immunotherapy, and biological therapy; however, overall patient survival remains suboptimal. Nanotechnology has ushered in a new era by offering innovative nanomaterials with the potential to precisely target cancer cells while sparing healthy tissues. It holds the potential to reshape the landscape of cancer management, offering hope for patients and clinicians. The assessment of these nanotechnologies follows a rigorous evaluation process similar to that applied to chemical drugs, which includes considerations of their pharmacokinetics, pharmacodynamics, toxicology, and clinical effectiveness. However, because of the characteristics of nanoparticles, standard toxicological tests require modifications to accommodate their unique characteristics. Effective therapeutic strategies demand a profound understanding of the disease and consideration of clinical outcomes, physicochemical attributes of nanomaterials, nanobiointeractions, nanotoxicity, and regulatory compliance to ensure patient safety. This review explores the promise of nanomedicine in lung cancer treatment by capitalizing on its unique physicochemical properties. We address the multifaceted challenges of lung cancer and its tumor microenvironment and provide an overview of recent developments in nanoplatforms for early diagnosis and treatment that can enhance patient outcomes and overall quality of life.
- 31 December 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (9) , 13197-13220
Open AccessNanomedicine Innovations for Lung Cancer Diagnosis and Therapy
Lung cancer remains a challenge within the realm of oncology. Characterized by late-stage diagnosis and resistance to conventional treatments, the currently available therapeutic strategies encompass surgery, radiotherapy, chemotherapy, immunotherapy, and biological therapy; however, overall patient survival remains suboptimal. Nanotechnology has ushered in a new era by offering innovative nanomaterials with the potential to precisely target cancer cells while sparing healthy tissues. It holds the potential to reshape the landscape of cancer management, offering hope for patients and clinicians. The assessment of these nanotechnologies follows a rigorous evaluation process similar to that applied to chemical drugs, which includes considerations of their pharmacokinetics, pharmacodynamics, toxicology, and clinical effectiveness. However, because of the characteristics of nanoparticles, standard toxicological tests require modifications to accommodate their unique characteristics. Effective therapeutic strategies demand a profound understanding of the disease and consideration of clinical outcomes, physicochemical attributes of nanomaterials, nanobiointeractions, nanotoxicity, and regulatory compliance to ensure patient safety. This review explores the promise of nanomedicine in lung cancer treatment by capitalizing on its unique physicochemical properties. We address the multifaceted challenges of lung cancer and its tumor microenvironment and provide an overview of recent developments in nanoplatforms for early diagnosis and treatment that can enhance patient outcomes and overall quality of life.
- 1 December 2021
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 66
Rational design of nanocarriers based on gellan gum/retrograded starch exploiting polyelectrolyte complexation and ionic cross-linking processes: A potential technological platform for oral delivery of bevacizumab
- 1 December 2021
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 66
Rational design of nanocarriers based on gellan gum/retrograded starch exploiting polyelectrolyte complexation and ionic cross-linking processes: A potential technological platform for oral delivery of bevacizumab
- 1 December 2020
- Published by Elsevier in Carbohydrate Polymers
- Vol. 250, 116968
Design of chitosan-based particle systems: A review of the physicochemical foundations for tailored properties
- 1 December 2020
- Published by Elsevier in Carbohydrate Polymers
- Vol. 250, 116968
Design of chitosan-based particle systems: A review of the physicochemical foundations for tailored properties
- 1 August 2020
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 153, 273-284
Chick embryo chorioallantoic membrane as a suitable in vivo model to evaluate drug delivery systems for cancer treatment: A review
- 1 August 2020
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 153, 273-284
Chick embryo chorioallantoic membrane as a suitable in vivo model to evaluate drug delivery systems for cancer treatment: A review
- 1 April 2020
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 149, 234-245
Mucin-polysaccharide interactions: A rheological approach to evaluate the effect of pH on the mucoadhesive properties
- 1 April 2020
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 149, 234-245
Mucin-polysaccharide interactions: A rheological approach to evaluate the effect of pH on the mucoadhesive properties
- 1 February 2018
- Published by Elsevier in European Polymer Journal
- Vol. 99, 117-133
Recent advances in smart hydrogels for biomedical applications: From self-assembly to functional approaches
- 1 February 2018
- Published by Elsevier in European Polymer Journal
- Vol. 99, 117-133
Recent advances in smart hydrogels for biomedical applications: From self-assembly to functional approaches
- 25 May 2017
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 43 (10) , 1656-1668
A novel pH-responsive hydrogel-based on calcium alginate engineered by the previous formation of polyelectrolyte complexes (PECs) intended to vaginal administration
This work aimed to develop a calcium alginate hydrogel as a pH responsive delivery system for polymyxin B (PMX) sustained-release through the vaginal route. Two samples of sodium alginate from different suppliers were characterized. The molecular weight and M/G ratio determined were, approximately, 107 KDa and 1.93 for alginate_S and 32 KDa and 1.36 for alginate_V. Polymer rheological investigations were further performed through the preparation of hydrogels. Alginate_V was selected for subsequent incorporation of PMX due to the acquisition of pseudoplastic viscous system able to acquiring a differential structure in simulated vaginal microenvironment (pH 4.5). The PMX-loaded hydrogel (hydrogel_PMX) was engineered based on polyelectrolyte complexes (PECs) formation between alginate and PMX followed by crosslinking with calcium chloride. This system exhibited a morphology with variable pore sizes, ranging from 100 to 200 μm and adequate syringeability. The hydrogel liquid uptake ability in an acid environment was minimized by the previous PECs formation. In vitro tests evidenced the hydrogels mucoadhesiveness. PMX release was pH-dependent and the system was able to sustain the release up to 6 days. A burst release was observed at pH 7.4 and drug release was driven by an anomalous transport, as determined by the Korsmeyer-Peppas model. At pH 4.5, drug release correlated with Weibull model and drug transport was driven by Fickian diffusion. The calcium alginate hydrogels engineered by the previous formation of PECs showed to be a promising platform for sustained release of cationic drugs through vaginal administration.
- 25 May 2017
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 43 (10) , 1656-1668
A novel pH-responsive hydrogel-based on calcium alginate engineered by the previous formation of polyelectrolyte complexes (PECs) intended to vaginal administration
This work aimed to develop a calcium alginate hydrogel as a pH responsive delivery system for polymyxin B (PMX) sustained-release through the vaginal route. Two samples of sodium alginate from different suppliers were characterized. The molecular weight and M/G ratio determined were, approximately, 107 KDa and 1.93 for alginate_S and 32 KDa and 1.36 for alginate_V. Polymer rheological investigations were further performed through the preparation of hydrogels. Alginate_V was selected for subsequent incorporation of PMX due to the acquisition of pseudoplastic viscous system able to acquiring a differential structure in simulated vaginal microenvironment (pH 4.5). The PMX-loaded hydrogel (hydrogel_PMX) was engineered based on polyelectrolyte complexes (PECs) formation between alginate and PMX followed by crosslinking with calcium chloride. This system exhibited a morphology with variable pore sizes, ranging from 100 to 200 μm and adequate syringeability. The hydrogel liquid uptake ability in an acid environment was minimized by the previous PECs formation. In vitro tests evidenced the hydrogels mucoadhesiveness. PMX release was pH-dependent and the system was able to sustain the release up to 6 days. A burst release was observed at pH 7.4 and drug release was driven by an anomalous transport, as determined by the Korsmeyer-Peppas model. At pH 4.5, drug release correlated with Weibull model and drug transport was driven by Fickian diffusion. The calcium alginate hydrogels engineered by the previous formation of PECs showed to be a promising platform for sustained release of cationic drugs through vaginal administration.